跳转至内容
Merck
CN

779717

19-羟基-4-雄甾烯-3,17-二酮

≥90% (HPLC)

别名:

19-羟基雄烯二酮, 4-雄甾烯-3,17-二酮-19-醇

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H26O3
化学文摘社编号:
分子量:
302.41
EC Number:
208-116-5
UNSPSC Code:
12352103
PubChem Substance ID:
Beilstein/REAXYS Number:
2567249
MDL number:
Assay:
≥90% (HPLC)
Form:
crystals
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C19H26O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10,14-16,20H,2-9,11H2,1H3/t14-,15-,16-,18-,19+/m0/s1

InChI key

XGUHPTGEXRHMQQ-BGJMDTOESA-N

SMILES string

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34CO)[C@@H]1CCC2=O

assay

≥90% (HPLC)

form

crystals

optical activity

[α]/D +190±5°, c = 1 in chloroform

storage temp.

−20°C

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

pictograms

Health hazard

signalword

Warning

hcodes

pcodes

Hazard Classifications

Repr. 2

存储类别

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

H Sekihara et al.
Clinical endocrinology, 39(5), 557-560 (1993-11-01)
We have reported that 19-hydroxyandrostenedione (19-OH-A-dione) functions as an amplifier of the sodium-retaining and hypertensive action of aldosterone. We therefore measured 19-hydroxyandrostenedione in hypertensive patients. We studied 53 normal male control subjects and 63 male patients with essential hypertension (48
H Morita et al.
Endocrine journal, 40(1), 89-97 (1993-02-01)
The present study was performed to clarify changes in plasma levels of 19-hydroxyandrostenedione (19-OH-AD), an amplifier of aldosterone and a possible hypertensinogenic steroid, during several tests for the renin-angiotensin system in 20 patients with aldosterone-producing adenoma (APA) and to determine
S Ohnishi et al.
Steroids, 55(1), 5-9 (1990-01-01)
19-Hydroxyandrostenedione (19-OHA), highly labeled with deuterium at position 7, was synthesized from unlabeled androstenediol diacetate. The deuterium labels were introduced into the 7-keto compound with dichloroaluminum deuteride to obtain [7-2H2]androstenediol. The labeled androstenediol diacetate was converted to the labeled 19-OHA
M Minato et al.
Nihon Naibunpi Gakkai zasshi, 66(1), 29-41 (1990-01-20)
In order to evaluate the hypertensinogenic action of 19-hydroxyandrostenedione (19-OH-AD), which has been reported to be an amplifier of mineralocorticoid, the changes in several humoral factors were observed in 19-OH-AD treated rats as compared to those in DOCA hypertensive rats.
K Higuchi et al.
Endocrinologia japonica, 36(6), 881-885 (1989-12-01)
The steroid, 19-hydroxyandrost-4-ene-3, 17-dione (19-hydroxyandrostene-dione, 19-OH-A-dione) has been known to enhance the mineralocorticoid action of aldosterone. To investigate the age-related change in the plasma 19-OH-A-dione concentration, plasma 19-OH-A-dione, androst-4-ene-3, 17-dione (A-dione), aldosterone and cortisol of 38 non-hypertensive healthy subjects (18

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持